The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hydroxychloroquine (HCQ), with the chemical formula C18H26ClN3O, is a chemotherapeutic agent drug that is primarily used for the prevention and treatment of malaria. It acts against erythrocytic forms of malarial parasites and is majorly administered in the form of an oral tablet. It is also used for the treatment of various other diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Q fever and Porphyria Cutanea Tarda (PCT) and is being examined for the possible treatment of the rapidly spreading COVID-19 disease. It exhibits immunosuppressive, anti-autophagy and antimalarial properties as it suppresses immune functions and presents antigens and cytokines in the body.
The sudden outbreak of the COVID-19 pandemic across the globe is one of the key factors driving the growth of the market. Various clinical trials and experiments are being conducted across the globe to analyze the efficacy and safety of hydroxychloroquine for the treatment of adults hospitalized with the coronavirus disease. The increasing prevalence of malaria and various other chronic diseases, especially in developing and underdeveloped countries, is also leading to the widespread adoption of this drug. In line with this, the rapidly rising cases of autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, are acting as another growth-inducing factor. Other factors, including the implementation of favorable government policies to promote global health, along with extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hydroxychloroquine market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on dosage type, distribution, application, grade and route of administration.
Breakup by Dosage Type:
Breakup by Distribution:
Breakup by Application:
Breakup by Grade:
Breakup by Route of Administration:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma, Zydus Cadila, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Dosage Type, Distribution, Application, Grade, Route of Administration, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma and Zydus Cadila|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at